Home/Pipeline/SBX 2000

SBX 2000

Cardiovascular Diseases

Early-stage ClinicalActive

Key Facts

Indication

Cardiovascular Diseases

Phase

Early-stage Clinical

Status

Active

Company

Stramsen Biotech

About Stramsen Biotech

Stramsen Biotech is an early-stage, private biotech firm pioneering a plant-based drug discovery and development platform. It boasts a robust pipeline of 33 drug candidates, with 11 in early-stage clinical trials, targeting major therapeutic areas including oncology, cardiovascular disease, HIV, and diabetes. The company claims a $19 billion valuation from a third-party appraisal and is backed by lead investor GEM Global Yield LLC SCS, positioning it for significant growth as it advances candidates toward FDA submissions.

View full company profile

Therapeutic Areas

Oncology Cardiovascular Diseases Infectious Disease (HIV)Metabolic Disorders (Diabetes)Neurological Disorders Musculoskeletal Disorders (Arthritis)Urology Wound Care Nephrology

Other Cardiovascular Diseases Drugs

Drug	Company	Phase	Status
Anti-platelet	Dawah Pharmaceuticals	Development	Active
Autonomic Therapy Initiative (ATI)	BIOS Health	Pre-clinical	Active
Cardiology Diagnostics Program	Aptus Biosciences	Discovery	Active
Cardiovascular Collaboration	Unnatural Products	Discovery	Active
Not specified on provided pages	Cadila Pharmaceuticals	Commercial (World's First Claim)	Marketed
Cardiovascular Biomarkers R&D	Firalis	Development	Active
EPS222	Eusol Biotech	Preclinical	Active